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Notes 
THEY CALL THAT NATURAL?  AN ANALYSIS 
OF THE TERM “NATURALLY OCCURRING” 
AND THE APPLICATION OF GENES TO THE 
PATENT ACT 
I.  INTRODUCTION 
The controversy over the patentability of human genes has existed 
for decades.1  Improper monopolization of nature remains one of the 
main challenges to the patentability of genes.2  The comments to the 
United States Patent Act (“Patent Act”) state that naturally occurring 
substances are not patentable subject matter.3   However, the federal 
                                                 
1 See Lisa Kole & David Loretto, Patent Law Evolving to Meet Bioinformatics:  Genomics 
Revolution has Spawned Innumerable Patentable Inventions, but Pitfall Exists, 231 NEW L.J. 1, 3 
(2004); Burton T. Ong, Patenting Biological Bounty of Nature:  Re-examining the Status of 
Organic Inventions as Patentable Subject Matter, 8 MARQ. INTELL. PROP. L. REV. 1, 2 (2004) 
(noting that this controversy not only surrounds the patentability of genes, but also the 
patentability of other biotechnological subject matter including tissue culture, genetically 
altered microorganisms, and multicellular mammalian life forms). 
2 Kole, supra note 1, at 3. 
3 See 35 U.S.C.S. § 101 note 41 (LexisNexis 2000); see also infra note 68 (discussing that 
phenomena of nature are not patentable because they are the basic tools of scientific 
research and technological work); infra note 69 (discussing that natural phenomena are not 
the kind of discoveries that 35 U.S.C. § 101 was enacted to protect).  Compare infra note 70 
(discussing the theory that laws of nature are free to all  men and reserved exclusively to 
none), with 35 U.S.C. § 103 (2000).  Section 103 specifically states the requirement of 
nonobviousness as follows: 
(a) A patent may not be obtained though the invention is not 
identically disclosed or described as set forth in section 102 of this title, 
if the differences between the subject matter sought to be patented and 
the prior art are such that the subject matter as a whole would have 
been obvious at the time the invention was made to a person having 
ordinary skill in the art to which said subject matter pertains. 
Patentability shall not be negatived by the manner in which the 
invention was made. 
(b) (1) Notwithstanding subsection (a), and upon timely election by the 
applicant for patent to proceed under this subsection, a 
biotechnological process using or resulting in a composition of matter 
that is novel under section 102 and nonobvious under subsection (a) of 
this section shall be considered nonobvious if— 
 (A) claims to the process and the composition of matter are 
contained in either the same application for patent or in separate 
applications having the same effective filing date; and 
 (B) the composition of matter, and the process at the time it was 
invented, were owned by the same person or subject to an obligation 
of assignment to the same person. 
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circuit and Supreme Court have maneuvered around this obstacle by 
holding that naturally occurring substances, when purified and isolated 
from their natural environment, become patentable subject matter 
because they have been manipulated by the inventor and are no longer 
in their natural state.4  Furthermore, § 103 of the Patent Act specifically 
allows for a patent to issue on nucleotides, which are the natural 
                                                                                                             
 (2) A patent issued on a process under paragraph (1) — 
 (A) shall also contain the claims to the composition of matter used 
in or made by that process, or 
 (B) shall, if such composition of matter is claimed in another 
patent, be set to expire on the same date as such other patent, 
notwithstanding section 154. 
 (3) For purposes of paragraph (1), the term “biotechnological 
process” means— 
 (A) a process of genetically altering or otherwise inducing a 
single- or multi-celled organism to— 
 (i) express an exogenous nucleotide sequence, 
 (ii) inhibit, eliminate, augment, or alter expression of an 
endogenous nucleotide sequence, or 
 (iii) express a specific physiological characteristic not naturally 
associated with said organism; 
 (B) cell fusion procedures yielding a cell line that expresses a 
specific protein, such as a monoclonal antibody;  and 
 (C) a method of using a product produced by a process defined 
by subparagraph (A) or (B), or a combination of subparagraphs (A) 
and (B). 
35 U.S.C. § 103. 
4 See In re Bergstrom, 427 F.2d 1394, 1401–02 (1970); see also DONALD S. CHISUM, CHISUM 
ON PATENTS 61 (2004) (discussing that  the naturally occurring bar is sometimes used as a 
last resort to disqualify matter as patentable under the novelty and nonobviousness 
requirement of the patent act); see infra notes 115–20 and accompanying text (discussing 
that isolated and purified biological products qualify as new products to fulfill the novelty 
requirement for eligible patent material).  The novelty requirement consists of the 
following: 
A person shall be entitled to a patent unless— 
(a) the invention was known or used by others in this country, or 
patented or described in a printed publication in this or a foreign 
country, before the invention thereof by the applicant for patent, or 
(b) the invention was patented or described in a printed publication in 
this or a foreign country or in public use or on sale in this country, 
more than one year prior to the date of the application for patent in the 
United States, or 
. . . . 
(f) he did not himself invent the subject matter sought to be patented[.] 
35 U.S.C. § 102 (2000).  Isolation is defined as a procedure in which an organism present in 
an environment is obtained in pure culture.  Life Science Dictionary, http://biotech.icmb. 
utexas.edu/search/dict-search.mhtml (last visited Jan. 3, 2006).  Purification is defined as 
the process of isolating a product into a pure form.  Biology Online, http://www.biology-
online.org/dictionary.asp (last visited Jan. 3, 2006). 
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building blocks of genes.5  Regardless of this precedent, commentators 
continue to argue that manipulation of a natural object does not alter its 
natural state and therefore genes should be removed from patentable 
subject matter.6 
The problem with the federal circuit and Supreme Court’s reasoning 
can best be exemplified by the following comparison.7  Compare a field 
of grass to a strand of DNA.  Furthermore, compare a blade of grass to a 
gene.  While the blade of grass remains in the field, it is in its natural 
environment.8  Similarly, while a gene is attached to its DNA strand, it 
also is in its natural environment.9  Both the blade of grass as well as the 
gene can be said to be naturally occurring.10  When the blade of grass is 
plucked from its root, it has been isolated from the rest of the field.11  
Comparably, a gene becomes isolated when it is purified from its DNA 
strand.12  In the situation of the blade of grass, one can hardly argue that 
the blade extracted from the field is a completely different blade of grass 
than when it was still attached to the ground.13  However, in the case of a 
gene, the United States Patent and Trademark Office (“USPTO”) has 
stated that an excised gene is not the same as a gene in its natural 
environment; the process of pulling the gene from its environment 
presumably results in such manipulation that it is no longer naturally 
occurring.14  
The current understanding of the implication of the term “naturally 
occurring” on the Patent Act is the nucleus of the argument this Note 
presents.15   The Supreme Court has held that an object is naturally 
                                                 
5 See supra note 3 (discussing the incorporation of nucleotides into the Patent Act); see 
infra notes 45–47 and accompanying text (defining a nucleotide). 
6 See infra notes 17–18 and accompanying text (discussing the theory that genes are not 
naturally occurring and the United States Patent and Trademark Office’s response to this 
argument). 
7 This hypothetical attempts to compare a naturally occurring microscopic object with a 
naturally occurring macroscopic object in order to demonstrate that  even though 
manipulation has occurred, the macroscopic object is still the same object. 
8 See infra Part II.E (discussing the meaning of natural). 
9 See infra Part II.B (discussing the natural environment of a gene). 
10 See infra Part II.E (discussing the meaning of natural). 
11 See infra notes 114–22 and accompanying text (discussing the process of isolation and 
purification). 
12 See infra notes 114–22 and accompanying text. 
13 On a macroscopic level, it is much easier to understand that the two are the same, the 
blade still attached to the ground and the blade once severed from the ground. 
14 See infra note 17 and accompanying text (discussing the theory that genes are not 
naturally occurring and the USPTO’s response to this argument). 
15 See infra Parts II.E, III.A. 
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occurring when it has the same effect it always has, there is no greater 
utility created by the manipulation, and the subject performs in its own, 
naturally-determined manner. 16   The USPTO has narrowed the 
application of genes to this holding by qualifying genes as compositions 
of matter and thus patentable under the Patent Act.17  However, critics of 
this argument have qualified genes as naturally occurring on the basis 
that owning life is a form of secular sacrilege.18  There is an extreme need 
to determine what constitutes a natural substance and is therefore not 
patentable under the Patent Act.19   Because biotechnology is constantly 
progressing, the Patent Act must be amended to clearly define a 
composition of matter so as to exclude naturally occurring genes from 
patentable subject matter.20  
Part II of this Note discusses current definitions of the terms “gene” 
and “natural” followed in congressional and judicial reasoning 
concerning these terms and their application to § 101 and § 103 of the 
Patent Act.21  It concludes with policy arguments emphasizing the need 
                                                 
16 See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948) (discussing that 
bacteria taken from the nodules of certain plants were naturally occurring and thus not 
patentable subject matter). 
17 See Utility Examination Guidelines, 66 Fed. Reg. 1093, 1093 (Jan. 5, 2001).  The USPTO 
strengthened this argument by stating that an excised gene is eligible for a patent because 
the DNA molecule does not naturally occur in an isolated form in nature.  Id.  In support of 
this argument, the USPTO stated that gene excision is not a new process and that the 
patentability of excised products of nature is well established.  Id.  The USPTO cited to 
several authorities to strengthen its opinion that genes are patentable.  Id.  First, in 1873 a 
patent was issued for a form of yeast that was free from all organic forms of germs and 
therefore was not naturally occurring.  U.S. Patent No. 141,072 (issued July 22, 1873).  Next, 
the USPTO alluded to a Supreme Court case holding that adrenaline was patentable subject 
matter because adrenaline does not occur in nature in a purified form.  Utility Examination 
Guidelines, 66 Fed. Reg. at 1093 (quoting Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 
(S.D.N.Y. 1911)).  The USPTO concluded that the Supreme Court decision established that 
even if the patentable subject matter were merely extracted from a product without a 
change in its composition, it would still be patentable upon extraction because it became a 
new object.  Id.  The USPTO relied on another case to determine that genes are patentable 
because they do not exist in a pure form in nature.  Utility Examination Guidelines, 66 Fed. 
Reg. at 1093 (quoting In re Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970)).  The comparison 
drawn here was between purified prostaglandins and purified genes.  Id.  In re Bergstrom 
established that prostaglandins do not exist in nature in a pure and isolated form and are 
patentable.  Id.  Therefore, the argument made by the USPTO is that genes do not exist in a 
pure form in nature and are also patentable.  Id.  The USPTO concluded this argument on 
the basis of prior case law and stated a patent on a gene covers the isolated and purified 
form of the gene because such form of the gene does not occur in nature.  Id. 
18 See Ong, supra note 1, at 4; see also Robert P. Merges, Intellectual Property in Higher Life 
Forms:  The Patent System and Controversial Technologies, 47 MD. L. REV. 1051, 1058–60 (1988). 
19 See infra Part III.A. 
20 See infra Part IV. 
21 See infra Part II. 
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to excise genes from the category of patentable subject matter.22  Part III 
addresses the concern raised by allowing genes to be patentable subject 
matter and attempts to establish that genes should not be included 
because they are naturally occurring entities.23   Part IV proposes an 
amendment to § 103 of the Patent Act to be utilized when determining 
whether an object is naturally occurring.24 
II.  BACKGROUND 
This Note analyzes several relevant topics in order to adequately 
address whether genes should be considered patentable subject matter.25  
To begin, an explanation of the historical and definitional analysis of a 
gene as applied to the Patent Act establishes the manner in which the 
USPTO treats the patentability of genes.26  Furthermore, case law dealing 
with products of nature explain the current understanding of patentable 
subject matter.27  Philosophical arguments concerning the term “nature” 
are also introduced to demonstrate more traditional understandings of 
the term that aid in appropriately addressing the ethical issues involved 
                                                 
22 See infra Part II.G. 
23 See infra Part III. 
24 See infra Part IV. 
25 See 35 U.S.C. §§ 101–03 (2000).  But see Ong, supra note 1, at 2 (suggesting that the 
“products of nature” objection has been used as a short form for rejecting a patent based on 
failure to meet the other specified requirements for patentability:  novelty, utility, and 
nonobviousness).  In Merck & Co. v. Olin Mathieson Chemical Corp., the court stated: 
 The Patent Act of 1952 as its predecessors [did], authorizes a 
patent for “any new and useful . . . composition of matter . . . ,” 
provided only that the conditions for patentability, which are specified 
in succeeding sections, are met.  There is nothing in the language of the 
Act which precludes the issuance of a patent upon a “product of 
nature” when it is a “new and useful composition of matter” and there 
is compliance with the specified conditions for patentability.  All of the 
tangible things with which man deals and for which patent protection 
is granted are products of nature in the sense that nature provides the 
basic source materials.  The “matter” of which patentable new and 
useful compositions are composed necessarily includes naturally 
existing elements and materials . . . . 
 A product of nature which is not a “new and useful . . . machine, 
manufacture, or composition of matter” is not patentable, for it is not 
within the statutory definition of those things which may be patented.  
Even though it be a new and useful composition of matter it still may 
be unpatentable if the subject matter as a whole was obvious within 
the meaning of § 103, or if other conditions of patentability are not 
satisfied. 
253 F.2d 156, 161–62 (4th Cir. 1958). 
26 See infra Parts II.A–C. 
27 See infra Part II.D. 
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with the patentability of genes.28  Finally, policy issues are relevant to 
this discussion because they demonstrate current political interpretations 
of the term “naturally occurring.”29 
A.   Short History of Genetics 
Genes have played a role in the composition of life since the dawn of 
time; however, it was not until recently that man has discovered them.30  
The history of modern genetics began in 1863 when Gregor Mendel, in 
his study of peas, discovered that traits are transmitted from parents to 
progeny by independent units called genes. 31    His observations 
established the groundwork for genetics.32  Close to one century later, 
Oswald Avery, Colin MacLeod, and Maclyn McCarty published a paper 
describing the transforming principle of genetic material as DNA, 
beginning the era of molecular genetics.33  One of the largest discoveries 
in the field of genetics, the discovery of the double helical structure of 
DNA occurred in 1953 and is attributed to Watson and Crick.34  In the 
past half century, the field of molecular genetics has progressed at an 
                                                 
28 See infra Part II.E. 
29 See infra Parts II.F–G. 
30 See Kelly Owens et al., Genomic Views of Human History, SCI., Oct. 15, 1999, at 451 
(discussing the genetic controversies concerning several different populations including the 
Nile Valley people and the Ashkenazi Jews from as early as 1991 BC); see also Robert 
Koenig, Uphill Battle to Honor Monk who Demystified Heredity, SCI., Apr. 7, 2000, at 37 
(discussing the work of Gregor Mendel from only 100 years ago, which can be considered a 
short time in the history of evolution). 
31 WILLIAM S. KLUG & MICHAEL R. CUMMINGS, CONCEPTS OF GENETICS 46 (Sheri L. 
Snavely ed., 6th ed. 2000) (1997).  Gregor Mendel’s obituary stated that he was a “man of 
the noblest character, one who was a warm friend, a promoter of the natural sciences, and 
an exemplary priest.”  Id. 
32 Id. 
33 Id. at 287.  Originally, protein was thought to be the biomolecule responsible for 
heredity.  Id.  However, this paper was the first time DNA was offered with experimental 
proof as the biomolecule responsible for heredity.  Id. 
34 Id.  Watson lobbied for the creation of the Human Genome Project and in 1988 became 
its director, a position he kept for the first four years.  See 
proof as the biomolecule responsible for heredity.  Id. 
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are against the patenting of genes argue that the incentive of a patent is 
unnecessary to encourage additional discovery or sequencing of genes 
because research alone satisfies intellectual curiosity.141   
The economic benefits of investment are another concern created by 
the patentability of genes.142  When biotech prospectors are successful in 
achieving a cure to a disease or developing a medicine, they stand to 
make a large return on their initial investment.143  Failure to grant a 
patent to researchers and investors impairs investors’ ability to earn a 
return on their investments.144  As a result, funding from the private 
sector could quickly dry up, and genetic research would be negatively 
affected.145  Furthermore, investment in the field of genetic research is 
already a risky concept.146  If public domain researchers are successful in 
getting as much of their research as possible into the public domain, then 
                                                                                                             
even though other discoveries may not have the ethical issues attached to them that genes 
do, this fact should not be a basis to exclude a patent because other discoveries get the 
benefit.  Id. 
141 Id. at 526.  The race for scientific discovery is another motivator that could potentially 
take the place of patents.  See Ko, supra note 139, at 793. 
142 Utility Examination Guidelines, 66 Fed. Reg. 1093, 1094 (Jan. 5, 2001).  The Guidelines 
specifically state the following: 
[W]hen a patent claiming a new chemical compound issues, the 
patentee has the right to exclude others from making, using, offering 
for sale, selling, or importing the compound for a limited time. The 
patentee is required to disclose only one utility, that is, teach others 
how to use the invention in at least one way. The patentee is not 
required to disclose all possible uses, but promoting the subsequent 
discovery of other uses is one of the benefits of the patent system. 
When patents for genes are treated the same as for other chemicals, 
progress is promoted because the original inventor has the possibility 
to recoup research costs, because others are motivated to invent 
around the original patent, and because a new chemical is made 
available as a basis for future research. Other inventors who develop 
new and nonobvious methods of using the patented compound have 
the opportunity to patent those methods. 
Id. 
143 Byron V. Olsen, The Biotechnology Balancing Act:  Patents for Gene Fragments, and 
Licensing the “Useful Arts”, 7 ALB. L.J. SCI. & TECH.  295, 298 (1997).  There is a commercial 
need to protect the investors.  See Andrews, supra note 135 (quoting Lisa Raines, vice 
president of government affairs at the Genzyme corporation in Cambridge, Massachusetts, 
stating that “biotechnology companies must raise tens of millions of dollars years before 
they have a marketable product, and patents provide the only assurance of being able to 
profit in the event that high-risk research is successful”). 
144 Barbara Looney, Should Genes be Patented?  The Gene Patenting Controversy:  Legal, 
Ethical, and Policy Foundations of an International Agreement, 26 LAW & POL’Y INT’L BUS. 231, 
234 (1994).  Researchers have provided a significant benefit to society and should therefore 
be rewarded by a return for their efforts.  Id. 
145 Id. at 244. 
146 Id. 
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private investors are likely to lose a substantial sum of money.147  If no 
patent protection existed and competitors were free to imitate a genetic 
product, prices would be driven down to the point that investors would 
not make a return on their investments.148   
The second argument regarding the concerns created by the 
patentability of genes involves impairment of scientific research.149  This 
argument can be broken down into several subsections that claim that 
patents on genes actually impair, rather than promote, scientific 
discovery. 150   The first subsection involves a waste of financial 
resources.151   Rebecca Eisenberg, a commentator on patenting genes, 
argues that when a researcher wants to study a new gene related to a 
gene that has already been claimed, the payment of royalties for use of 
that gene constitutes a waste of resources.152  Such use should be open to 
the public, and the money that would go to the payment of royalties 
should go to some other use to promote scientific discovery.153   
                                                 
147 See Olsen, supra note 143, at 307.  If a researcher gets his information out first, the 
novelty requirement of § 102 is destroyed and the subsequent investor loses his investment.  
Id. 
148 See Looney, supra note 144, at 231.  However, an argument could be made that even 
with patent protection there remains competition prior to the patent stage to the point that 
if another researcher wins the race to the patent finish line, the investor of the losing 
researcher loses all of his investment with no chance of making any return.  Id.  At least in 
the above stated instance, he would still have the chance to make some return depending 
on the fierceness of the market competition.  Id. 
149 See John T. Bontivoglio & Martha Cochran, Policy Issues Could Have Major Impact on 
Industry, NAT’L L.J., June 25, 2001, at C9 (discussing the problems created by patenting 
genes on discrimination and privacy of healthcare on patients involved in genetic 
research); Rebecca S. Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 742 (1990). 
150 See Utility Examination Guidelines, 66 Fed. Reg. 1093, 1095 (Jan. 5, 2001) (discussing 
the comments of several researchers expressing concern that DNA should be freely 
available for research, patents are not necessary to encourage additional discovery, and 
sequencing of genes and patenting of DNA inhibits biomedical research by allowing a 
single person or company to control use of the claimed DNA).  Furthermore, “patenting 
ESTs will impede complete characterization of genes and delay or restrict exploration of 
genetic materials for the public good.”  Id. 
151 See Eisenberg, supra note 149, at 737.  Eisenberg argues that with the amount of federal 
funding provided for genetic research, private funding is unnecessary.  Id. 
152 See Matthew Erramouspe, Staking Patent Claims on the Human Blueprint:  Rewards and 
Rent-Dissipating Races, 43 UCLA L. REV. 961, 996 (1996); see also McBride, supra note 140, at 
526. 
153 See Rebecca S. Eisenberg, Patents and the Progress of Science:  Exclusive Rights and 
Experimental Use, 56 U. CHI. L. REV. 1017, 1057 (1989); see also McBride, supra note 140, at 
526. 
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However, people who support the patentability of genes argue that 
the payment of royalties serves a beneficial purpose.154  It encourages 
incentive to design around the gene, which will actually further the goal 
of the Patent Act.155  Furthermore, in the event that designing around a 
gene is not possible, the researcher could develop a new process of 
achieving its goal and obtain a patent on the process as opposed to the 
composition.156  Proponents also argue that the field of research would 
become inefficient. 157   In the absence of patent protection, several 
researchers could independently be researching the same potential 
invention, resulting in inefficient duplicative research and a waste of 
funding.158  When placed on a worldwide level, misappropriation of 
resources proves to be severely inefficient.159 
Researchers argue that another impairment on scientific research 
created by the patentability of genes is secrecy in research labs. 160  
Secrecy in the labs inhibits dissemination of important information, 
slows progress, and ultimately limits the benefits to the public. 161  
Furthermore, § 102 provides a statutory bar to anyone that publishes 
information more than one year prior to the patent date, which also adds 
to the secrecy in the labs. 162   However, others argue that the exact 
opposite may be true. 163   Some researchers contend that the patent 
system is beneficial to the scientific community because without it, 
                                                 
154 McBride, supra note 140, at 525.  McBride offers four incentives that can be considered 
to include the incentive of royalties:  (1) incentive to invent, (2) incentive to disclose, (3) 
incentive to commercialize, and (4) incentive to design around.  Id. 
155 Id. at 527–28.  This concept is difficult to grasp.  When a scientist wants to study the 
effect of one gene upon another and either is already claimed by patent, it would seem 
impossible to design around the patented gene when it is the exact entity that must be 
studied.  Id.; see Eisenberg, supra note 153, at 1026–27. 
156 See Eisenberg, supra note 149, at 739 (arguing that it is difficult to prove and detect 
process patent infringement); McBride, supra note 140, at 523–24; see also Eisenberg, supra 
note 153, at 1028 (stating that patent protection may drive competitors to waste time and 
money on duplicate situations to avoid infringement). 
157 See Looney, supra note 144, at 236. 
158 Compare Looney, supra note 144, at 236, with Olsen, supra note 143, at 323 (stating 
patent protection actually runs the risk of inflating the price for research that can also be 
considered a waste of resources). 
159 Looney, supra note 144, at 236. 
160 See Eisenberg, supra note 153, at 1028–30; Eisenberg, supra note 149, at 745; Looney, 
supra note 144, at 237. 
161 See Eisenberg, supra note 153, at 1028–30. 
162 See 35 U.S.C. 102(b); see also Eisenberg, supra note 149, at 741. 
163 See Eisenberg, supra note 149, at 741. 
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scientists would be unprotected by a patent and would be forced to rely 
on secrecy to protect their discoveries.164   
Researchers argue that a final impairment on scientific research is the 
potential abuse of genetic information.165  The large amount of money 
invested in research and the desire to earn a return on these investments 
creates a need to achieve a return in unethical ways.166  Many firms are 
directing the information concerning genetic testing to the consumer and 
completely bypassing the doctor/patient relationship. 167   Researchers 
argue that such an approach will lead to a misuse of genetic testing and 
unnecessary medical costs.168  Another potential abuse is that during the 
licensing negotiations between certain researchers, a researcher may 
refuse to issue a license due to personal bias or on the basis of a 
professional threat. 169   Such occurrences could have a significantly 
detrimental impact on further gene research. 170   Ethical arguments 
regarding the abuse of genetic information are valid concerns, both 
presently as well as in the future.171 
The substantial backlog of gene applications in the USPTO is a final 
concern arguably created by the patentability of genes.172  Researchers 
have been rushing to identify as many gene sequences as possible to 
secure rights over them in the event these sequences ultimately become 
useful.173  Furthermore, the patentability of genes has spurred a race to 
                                                 
164 Id. at 742 (suggesting that this argument seems to disregard the fact that many 
scientists work in the pursuit of knowledge and the attributed recognition that 
accompanies a new discovery, not in the pursuit of dollars). 
165 Lori Andrews & Erin Shaughnessy Zuiker, Ethical, Legal, and Social Issues in Genetic 
Testing for Complex Genetic Diseases, 37 VAL. U. L. REV. 793, 814–15 (2003). 
166 Compare Andrews & Zuiker, supra note 165, at 815, with Ong, supra note 1, at 6 
(arguing that morality, ethical, and environmental concerns have no place in the patent 
system), and Carrie F. Walter, Beyond the Harvard Mouse:  Current Patent Practice and the 
Necessity of Clear Guidelines in Biotechnology Patent Law, 73 IND. L.J. 1025, 1026 (1998) 
(arguing that specialized commissions such as the National Bioethics Advisory 
Commission are better suited to deal with the moral and ethical dilemmas presented by 
biotechnology). 
167 See Andrews & Zuiker, supra note 165, at 815. 
168 Id.  People will demand unnecessary and potentially more harmful tests from their 
physicians when they meet little or none of the pre-screening criteria for such testing.  Id. 
169 See Eisenberg, supra note 153, at 1057. 
170 Id. 
171 Id. 
172 Notice of Meeting and Request for Public Comments on Oversite of Genetic Testing, 
64 Fed. Reg. 67,273, 67,275 (Dec. 1, 1999).  From 1980 to 1999, over 12,000 patents had been 
issued on plant, animal, and human genes; furthermore, applications had been filed for 
another 30,000 genes.  Id. 
173 Looney, supra note 144, at 231. 
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patent smaller pieces of DNA called express sequence tags (“ESTs”), 
typically of unknown function, to serve as probes for known genes.174  
Currently there are hundreds of thousands of applications waiting at the 
patent office.175  Such a backlog of genetic patents creates a problem 
because other inventions have to wait a significantly long time to achieve 
patent protection.176 
Ultimately, the USPTO sides with those in favor of the patentability 
of genes and strengthens this opinion by stating that isolated and 
purified genes are patentable because they are not naturally occurring.177  
However, the many different definitions of the terms “gene” and 
“naturally occurring” may lead to discrepancies in the ways these terms 
are applied to the Patent Act.178  Further analyzing these terms and their 
application to the Patent Act may lead to the conclusion that genes 
should not be patentable because they are naturally occurring.179 
III.  ANALYSIS 
This Part begins by addressing the need to properly define the terms 
“gene” and “natural” and presents the theory that the suggested 
definitions would render genes unpatentable under the Patent Act.180  
Part III.B addresses previous case law considering the term “naturally 
occurring” and provides possible outcomes resulting from the 
application of the suggested definition of “natural” from Part II. 181  
Finally, Part III.C offers solutions to the problems created by the 
patentability of genes.182  
                                                 
174 See Arti Kaur Rai, Regulating Scientific Research:  Intellectual Property Rights and the 
Norms of Science, 94 NW. U. L. REV. 77, 104 (1999) (explaining that ESTs are little bits of gene 
fragments and do not include the gene as a whole); see also Olsen, supra note 143, at 321–23 
(discussing gene fragment patentability). 
175 Human Genome Project Information, http://www.ornl.gov/sci/techresources/ 
Human_Genome/elsi/patents.shtml (last visited Jan. 31, 2005).  Currently there have been 
over three million genome-related patent applications filed at the USPTO.  Id. 
176 Id.  “In the case of genetic patenting, it is the scope and number of claims that has 
generated controversy.”  Id. 
177 See supra note 17 and accompanying text (discussing the USPTO’s inclusion of genes 
into the Patent Act as compositions of matter, and further qualifying isolated and purified 
genes as patentable subject matter because genes do not occur in nature in an isolated and 
purified form). 
178 See supra Parts II.B, II.E. 
179 See infra Part III.A. 
180 See infra Part III.A. 
181 See infra Part III.B. 
182 See infra Part III.C. 
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A. Genes as Natural Phenomena 
Although most definitions of the term “gene” agree that a gene is a 
functional unit, many leave the biochemical definition of a gene open or 
disagree on suggested definitions.183  The disagreement over the correct 
definition creates a problem when the Patent Act is applied regarding 
the non-naturally occurring statutory interpretation. 184   This Part 
discusses the functional definition of a gene and suggests that a naturally 
occurring function of a gene is to encode for specific aspects of 
inheritance.185  Furthermore, this Part analyzes the physical definition of 
a gene and the problems the current physical definitions present to § 101 
and § 103 of the Patent Act. 186   Finally, this Part offers a uniform 
definition of a gene in an attempt to resolve the problem created by the 
discrepancies between the current definitions.187 
To begin, almost all definitions of a gene state that a gene is a 
functional unit of inheritance.188  This definition can be broadened to 
suggest that a gene naturally serves as a functional unit of inheritance 
because even when a gene is purified and isolated, it retains the natural 
property of encoding for a particular polypeptide or other genetic 
material. 189   Therefore, the functional characteristic of a gene is the 
naturally occurring manifestation of the utility of the gene. 190   It is 
unaltered through the process of isolation and purification and should 
                                                 
183 See supra note 52 and accompanying text (offering definitions of a gene as a sequence 
coding for a polypeptide or an open reading frame of DNA).  But see supra text 
accompanying note 56 (offering a different definition of a gene as a specific chromosomal 
locus). 
184 See Ong, supra note 1, at 17 (noting the actual terms of the Patent Act and the 
disqualification of organic substances because they are imprecise, mutable, inconstant, and 
variable); see also Utility Examination Guidelines, 66 Fed. Reg. 1093, 1094 (Jan. 5, 2001) 
(discussing the USPTO encompassment of genes as patentable subject matter by their 
incorporation in the “composition of matter” provision of the patent act). 
185 See infra notes 188–92 and accompanying text. 
186 See infra notes 203–07 and accompanying text. 
187 See infra notes 201–02 and accompanying text. 
188 See supra text accompanying note 48; see also supra text accompanying note 52 (stating 
that a gene is a sequence coding for a specific polypeptide); supra text accompanying note 
55 (stating that a gene is a “unit of inherited material encoded by a strand of DNA”); supra 
text accompanying note 58 (stating that a gene is a functional unit of inheritance controlling 
the transmission and expression of one or more traits by specifying the particular structure 
of a polypeptide). 
189 See supra text accompanying note 81 (discussing that the function and performance of 
a bacterium can relate to the “naturalness of the bacteria”); see also supra text accompanying 
note 117 (discussing the patent board’s suggestion that a patent should not be issued unless 
the product exhibited properties and utilities not possessed by the unpurified material). 
190 See supra text accompanying note 48. 
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therefore be considered naturally occurring. 191   If this definition is 
applied to the Patent Act, a gene would not be patentable because it is 
naturally occurring.192  
Furthermore, the biochemical definition of a gene, which is its 
physical description, also has discrepancies that must be addressed to 
conclude that a gene is naturally occurring.193  In fact, it may be more 
important to solve the discrepancies of the biochemical definition than 
the discrepancies of the physical description because the term “naturally 
occurring” has traditionally been applied to the physical description 
rather than the function.194  Proof of this theory is offered through the 
inclusion of the term “composition of matter” in the Patent Act, which 
relates more to physical attributes than functional use.195   
Yet another issue is that most definitions suggest an exact location of 
the physical manifestation of a gene, i.e., the area of matter between start 
and stop codons or a specific locus on a chromosome.196  However, these 
definitions do not agree with each other and leave open the question as 
                                                 
191 See supra note 115 and accompanying text (discussing the isolation and purification 
processes). 
192 See supra text accompanying notes 67–72.  The functional definition of a gene is not the 
most important definition, but it must be addressed.  See supra text accompanying note 48.  
When considering what is naturally occurring, the mere tangible form of the substance is 
considered more than the functional service of the substance.  See supra note 112 (describing 
physical products that are considered natural based on their physical being).  Therefore, 
although an object may serve a naturally occurring function, it may be a manmade and 
altered substance, which would fulfill the requirements of the patent statute.  See supra text 
accompanying notes 112–13. 
193 See supra notes 55–60 and accompanying text. 
194 See supra text accompanying note 80 (discussing that the physical qualities of bacteria 
are manifestations of nature); see also supra text accompanying note 113 (stating that a 
patent could be secured for genetically engineered bacteria because they are non-naturally 
occurring compositions of matter).   The term “composition of matter” can allude to the 
physical quality of a product as opposed to the functional quality of the product.  See supra 
text accompanying note 120 (stating that human hormones do not exist in nature in the 
pure form).  The term “form” relates to the physical manifestation rather than the 
functional use.  See supra notes 44–60 and accompanying text for a comparison between 
“form” and “function.” 
195 See 35 U.S.C. § 112 (2000) (“The phrase ‘composition of matter’ with respect to 
granting application for patent covers all compositions of two or more substances and 
includes all composite articles, whether results of chemical union or of mechanical mixture, 
or whether they be gases, fluids, powders or solids.”).  The terms used in the definition of 
composition of matter describe the physical attributes but not the functional attributes of 
the substance.  See id.; see also 35 U.S.C. § 103. 
196 See supra text accompanying note 56; see also supra text accompanying note 59 
(discussing another definition suggesting that a gene includes the entire functional unit, 
encompassing DNA sequences, non-coding regulatory sequences, and introns). 
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to what exactly is the physical characteristic of a gene.197  The importance 
in deciding this issue lies in the problems presented by the purification 
and isolation techniques.198  Depending on which definition is applied, 
the techniques may leave the gene unaltered and thus in its natural 
state. 199   However, if the most specific definition is applied, the 
components included beyond the functional unit may change, thereby 
altering the gene as a whole.200 
Based on this analysis, the most logical definition of a gene would  
include the functional components (aspects that play a part in the role of 
heredity) with the physical biochemical components (the actual 
composition of the gene).  The excess components, such as the non-
coding regulatory DNA sequences, should be excluded from the 
definition because they only play regulatory roles in the expression of 
inheritance.201  The definition should define a gene in its narrowest sense, 
which results in the conclusion that a gene does not qualify as patentable 
subject matter.202 
The suggested definition of a gene also fulfills the definitions of the 
term “natural” and should therefore not be considered patentable.203  
The term “nature” has been defined as “the living world” and 
everything within it that makes it up; however, this definition is 
insufficient because it includes only the living world.204  One can imagine 
several objects that are considered natural that do not fall in the category 
                                                 
197 See supra notes 48–53 and accompanying text. 
198 See supra notes 4, 115 and accompanying text (discussing purification and isolation). 
199 See supra text accompanying notes 48–60 (describing the different possible definitions 
of a gene). 
200 See supra notes 48–60.  If the definition of a gene is simply the functional unit of the 
gene, then the process of isolation and purification, which do not alter the functional 
components, would leave the gene unaltered, thereby rendering the gene unchanged from 
its natural state.  See supra notes 48, 115 and accompanying text.  However, if the more 
specific definition is applied to include the encompassing DNA sequences, non-coding 
regulatory sequences, and introns, these specific particles may be altered by the process of 
isolation and purification.  See supra note 59 and accompanying text.  An alteration to these 
components would thereby be an alteration to the gene because they are included in the 
definition of what a gene entails.  See supra notes 48–60.  Therefore, the gene would no 
longer occur in its “natural” state and would qualify to become patentable subject matter.  
See supra notes 122–33 and accompanying text (discussing the term “natural”). 
201 See supra note 59 and accompanying text. 
202 By narrowing the suggested definition of a gene to only the functional components, 
with functional relating only to the function of the DNA sequence that codes for the 
specific protein, the gene will remain unaltered by the purification and isolation technique.  
See supra text accompanying note 4. 
203 See supra notes 122–33 and accompanying text. 
204 See supra note 124 (discussing the definition from the DICTIONARY OF SCIENCE). 
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of living.205  Another, more accurate, definition states that nature is the 
genetically controlled qualities of an organism.206  As stated in other 
Parts of this Note, the process of isolation and purification does not alter 
the actual genetics because the gene maintains its original function.207  
Therefore, a gene can fit into the definition of a naturally occurring 
product.208 
A gene also qualifies as a natural phenomenon under philosophical 
doctrines.209  Genes fit LaPorte’s theory that “naturalness” is promoted 
by the explanatory value of the object because the reason for the gene is 
explained by its functional definition.210  A gene is naturally comprised 
of inheritance information, and this natural function precisely defines a 
gene as a unit of hereditary information.211   Genes also fit Aristotle’s 
definition of nature’s design and rational plan because the biochemical 
design of a gene is a rational plan involving hereditary units that tell the 
gene what to do.212  Finally, Lovejoy’s theory of nature, as that which 
exists apart from and uninfluenced by man, can also be applied to genes 
because the isolation and purification technique does not affect the gene 
and its function at the most microscopic level.213  The gene remains in a 
natural state regardless of this technique.214  Genes can qualify as natural 
material based on philosophy as well as encyclopedic knowledge, and as 
such, genes do not qualify as patentable subject matter.215 
                                                 
205 See supra note 124.  For example, many of the smaller components of larger 
manifestations of life, such as personality and physiology, which are not themselves living, 
can be considered nature.  See supra note 16 and accompanying text. 
206 See supra note 124 (providing the definition from WEBSTER’S NEW WORLD 
DICTIONARY). 
207 See supra note 4 and accompanying text; see also supra note 115 and accompanying text. 
208 See supra notes 122–33 and accompanying text. 
209 See supra Part II.E. 
210 See LAPORTE, supra note 125, at 18; see also supra note 126 and accompanying text 
(discussing that the “natural” definition of an object is explained on the basis of why it does 
what it does, why it has certain traits, and why it uses certain mechanisms). 
211 See supra notes 48–53 and accompanying text (explaining the functional definition of a 
gene). 
212 See ALBERTS, supra note 46, at G15 (explaining the chemical composition of a gene and 
its design as it relates to the functional purpose); see also supra notes 130–31 and 
accompanying text; supra notes 132–33 and accompanying text (discussing Aquinas’s 
expansion on Aristotle’s philosophy by incorporating the theory that nature is described as 
the result of change). 
213 See supra notes 128–29 and accompanying text (discussing Lovejoy’s theory of nature). 
214 See supra note 115 and accompanying text. 
215 See supra Part II.E. 
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B. Differences in Court Opinions Regarding the Term “Naturally Occurring” 
Analyzing court holdings regarding the term “naturally occurring” 
further exemplifies that genes should not be considered patentable 
subject matter.216  Funk Brothers Seed217 helps illustrate why genes are 
naturally occurring because the bacteria in that case are comparable to 
genes; they both contain the elements of life.218   
The first pertinent aspect of the Court’s decision that is applicable to 
genes is the holding that the qualities of the bacteria are works of 
nature.219  The inventor in Funk Brothers Seed merely combined several 
existent strains of bacteria to form one strain that performs a desired 
task, which is comparable to the desired task of genes; when a gene is 
purified and isolated, the underlying characteristics of the gene remain 
unchanged.220  Regardless of how many genes are placed next to each 
other, each separate gene performs its own, naturally derived function.221   
The second area of importance in the Court’s decision that applies to 
genes is that the bacteria performed the way nature intended; 
furthermore, there was no improvement in their performance. 222  
Although genes can be used for many improvements in the scientific 
field, the use of the gene itself is not improved. 223   The gene only 
performs the task that it was naturally intended to perform—coding for 
a particular genetic trait.224 
                                                 
216 See supra Part II.D. 
217 333 U.S. 127, 128 (1948). 
218 Id.  It can be argued that bacteria are alive and genes are just components that enable 
life.  In other words, bacteria contain genes.  This argument does not change the underlying 
contention of this Note because both occur naturally in the free world. 
219 Id. 
220 See supra note 4 and accompanying text.  An almost universally accepted definition of 
a gene encompasses the fact that a gene is a unit of inheritance of a genetic characteristic.  
See supra notes 48–50 and accompanying text.  The precise function and purpose of a gene 
is therefore to display a certain characteristic.  See KLUG & CUMMINGS, supra note 31, at 757 
(implying that no matter what technique is used to obtain the gene, in its naturally 
occurring state, it cannot result in a characteristic different from the one for which  it 
codes). 
221 See supra notes 48–53 and accompanying text. 
222 Funk Bros. Seed, 333 U.S. at 132. 
223 See supra note 55 and accompanying text (describing a gene as a unit of inherited 
material encoded by DNA that describes what the gene is supposed to do).  This function is 
not changed upon removal from noncoding regions of DNA.  KLUG & CUMMINGS, supra 
note 31, at 49. 
224 See supra Part II.B (discussing the definition of how a gene functions). 
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Public policy concerns are another area addressed by the courts 
when dealing with naturally occurring products of nature. 225   The 
holding in O’Reilly, that monopolization of electromagnetism is against 
public policy, is also applicable to the potential monopolization of the 
scientific community created by patenting genes.226  Just as the inventor 
would be able to avail himself of any further discoveries using the power 
of electromagnetism according to O’Reilly, so too may a researcher with a 
patent on an important gene avail herself of any further discoveries 
created from the use of that gene.227  A strong public policy argument 
against allowing others to benefit from naturally occurring substances 
remains when the public as a whole could receive an enormous benefit 
from the substance.228  
The conjecture made in O’Reilly that Fulton, the inventor of the 
steam engine, could not have obtained a patent for the motive power of 
steam because it would prevent further progress and improvement to 
the engine is also applicable to the impairment on scientific research 
created by patenting genes.229  When others are restricted from using a 
gene, they are unable to make advances in scientific research.230  This 
hindrance could have an overall detrimental effect on society because 
society is not being availed of the latest technological advances.231 
Although the holdings from Funk Brothers Seed and O’Reilly 
demonstrate that genes should be considered naturally occurring, other 
cases concerning the term are distinguishable. 232   The holding in 
Chakrabarty is not applicable to genes even though bacteria and genes 
may qualify as compositions of matter because, unlike the bacteria in 
Chakrabarty, genes do not satisfy all other statutory requirements.233  One 
                                                 
225 See infra notes 83–92 and accompanying text. 
226 See O’Reilly v. Morse, 56 U.S. 63, 113 (1854). 
227 Id.; see also Eisenberg, supra note 153, at 1030 (discussing that the monopolization of 
scientific products creates the problem of secrecy in the labs because researchers want to 
achieve monopoly so they keep their work secret to society’s detriment). 
228 See supra notes 160–61 and accompanying text. 
229 See O’Reilly, 56 U.S. at 113. 
230 See Eisenberg, supra note 153, at 1030. 
231 See supra notes 161–69 and accompanying text (discussing the detrimental effect that 
patentability of genes could present to society as a whole).  Due to the large amount of 
money invested in research, practitioners may behave unethically and administer 
unnecessary genetic testing at a high rate to compensate for their investments.  Id.  This 
may lead to an abuse of genetic testing and unnecessary medical costs.  Id. 
232 See supra Part II.D (discussing the difference in court opinions regarding the term 
“naturally occurring”). 
233 Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980).  One of the problems addressed by 
the lower court was that living matter is not patentable.  Id. at 305.  Therefore, § 101 was not 
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of the underlying statutory requirements for patentability is that the 
objects to be patented must not naturally occur.234  Therefore, even if a 
product fulfills the composition of matter requirement, it must also fulfill 
all other requirements of patentable subject matter to qualify for a 
patent.235  If it were determined that genes are naturally occurring, it 
would make no difference whether they were compositions of chemical 
matter; they would not fulfill all statutory requirements and would thus 
not be patentable.236 
This argument leads to the second reason the Court held 
Chakrabarty’s bacteria patentable:  Chakrabarty had developed 
genetically engineered bacteria by combining the DNA of two bacteria 
into one.237  His feat was successful because he built a new object by 
taking two different objects and putting them together.238  This technique 
is different, in fact inapposite, to the technique used to obtain a gene.239  
In order to obtain a gene, one must go into an already existing and 
naturally occurring strand of DNA and excise the gene to be patented 
                                                                                                             
applicable and a patent could not be issued.  Id.  However, the Supreme Court addressed 
this issue and held that it is not a matter of deciding whether a product is living or 
nonliving because living organisms, when created by man, can be patentable.  Id. at 309.  
When this argument is presented against the patenting of genes, one could suggest that 
genes are components of living material that are not created by man.  See supra notes 183–
214 and accompanying text.  However, the aspect of living material verses the discussion of 
living organisms is rather attenuated and provides little support to the argument.  See 
Chakrabarty, 447 U.S. at 308 (discussing the Court’s definition of “composition of matter” as 
“all compositions of two or more substances and . . . all composite articles, whether they be 
the results of chemical union, or of mechanical mixture, or whether they be gases, fluids, 
powders or solids” ). 
234 See 35 U.S.C.S. § 101 note 41; see also supra notes 67–71 and accompanying text 
(discussing what qualifies as naturally occurring substances for patent invalidity). 
235 The USPTO has held that genes qualify as “chemical compositions of matter” and are 
therefore patentable.  See supra text accompanying note 110 (stating that genes are chemical 
compositions of matter and should not be treated differently than other compositions of 
matter).  However, the USPTO has also stated that as long as the gene’s chemical 
composition meets all other statutory requirements, there is no legal basis to reject it.  See 
supra note 17 and accompanying text; see also Ong, supra note 1, at 2 (stating that even if an 
organic compound qualifies as a “composition of matter,” if the core of the invention lies in 
its natural function, it should be considered a product of nature); see supra notes 99–101, 
110–13 (discussing the decision reached in Chakrabarty and the emphasis on other statutory 
requirements). 
236 See supra note 108 and accompanying text (discussing the definition of the term 
“composition of matter”). 
237 See Chakrabarty, 447 U.S. at 303. 
238 Id.  The key to this point in the analysis is that he performed addition to get the 
genetically modified bacteria; he had to utilize addition of two naturally occurring 
manifestations of nature, which by themselves would not qualify as patentable subject 
matter, and combine them to make a form that had never existed before.  Id. 
239 Id.; see also supra note 4 and accompanying text. 
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using an isolation and purification technique.240  The process requires the 
invasion into an already naturally occurring object and pulling out a 
component of it that is also in its naturally occurring state.241  It is much 
easier to realize that one is creating or inventing a new item when he 
combines two different naturally occurring objects into a non-naturally 
occurring object, than it is to realize that one is creating an object when 
he merely goes into a naturally occurring object and pulls an item out of 
it.242 
The next issue concerning the term “naturally occurring” is the 
federal circuit’s holding that the isolation and purification technique 
alters a natural product to the point that it can no longer be considered 
natural.243   In re Bergstrom discussed such a technique as applied to 
human hormones; however, more emphasis should have been placed on 
the patent board’s decision, which found that if the purified material did 
not exhibit properties and utilities not possessed by the unpurified 
material, it could not be issued a patent.244  This holding suggests that if 
the properties of the pure form are the same as the properties of the 
impure form, the pure form lacks the statutory requirement of novelty.245  
Application of the patent board’s theory to genes should result in a 
similar holding that genes should not be patentable.246  Genes satisfy the 
utility requirements of the patent statute largely because of their 
functions and physical uses in science and technology.247  In fact, it is 
often the exact function and utility of the gene that makes it a desirable 
subject for research in the first place.248  Because a gene has the same 
                                                 
240 See supra text accompanying note 17 (stating that the USPTO asserted that a DNA 
strand by itself is raw, fundamental, non-descriptive information that alone is not 
patentable). 
241 See supra Part II.E. 
242 Compare Chakrabarty, 447 U.S. at 303 (involving a process that required adding bacteria 
together), with In re Bergstrom, 427 F.2d 1394, 1396 (C.C.P.A. 1970) (involving a process 
where a purified product was pulled from an unpurified compound). 
243 See supra note 17 (discussing the USPTO’s argument that such modification alters the 
natural state of a gene to the point that it becomes manmade and thus patentable). 
244 In re Bergstrom, 427 F.2d at 1396. 
245 See supra notes 114–17 and accompanying text. 
246 The board found that both the pure and impure materials could stimulate smooth 
muscle cells and lower blood pressure.  See supra text accompanying note 117.  Likewise, a 
gene that is purified and isolated will have the same characteristics and properties as an 
impure gene in regards to the function of the gene, even though the actual physical 
manifestation of the gene may be different.  See supra text accompanying notes 4, 115. 
247 See supra note 65 and accompanying text (discussing the requirement of utility as 
being derived from the constitutional clause granting a patent for any new and useful 
machine, manufacture, or composition of matter). 
248 See supra notes 149–64 and accompanying text (discussing the research of genes for 
genetic testing as well as the substantial investments that are offered for research to occur). 
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function regardless of whether it is impure or pure and contains the 
same genetic code in either form, the purified material does not exhibit 
properties and utilities not possessed by the unpurified material. 249  
Therefore, according to the patent board’s decision, a gene would not be 
patentable subject matter.250 
However, even though the CCPA overruled the patent board by 
placing emphasis on the naturally occurring characteristics of the 
hormones and determining that the hormones do not exist in nature in 
the pure form, genes should not have the same fate.251   First of all, genes 
do occur in a pure form in nature at the most microscopic level because 
the fragments and extra attachment plaques that are removed by 
isolation and purification are not considered a part of the gene in the 
natural sense.252  Therefore, the removal of these materials leaves the 
original gene, as a whole, unaltered in an isolated and purified product, 
and so it is natural to the point that it is not patentable subject matter.253  
This argument also supports the second holding in In re Bergstrom, that 
the pure and isolated form of the hormone do not occur in nature’s 
storehouse.254  Relating this logic to genes, if it is determined that the 
pure and isolated form of a gene occur in a natural state in the DNA of a 
cell, then it follows that it occurs in nature’s storehouse.  Ultimately, the 
                                                 
249 See supra Part II.B (describing the genetic composition of a gene and the relation of the 
composition to the function of the gene). 
250 See supra notes 114–17 and accompanying text. 
251 In re Bergstrom, 427 F.2d 1394, 1396 (C.C.P.A. 1970); see supra notes 119–20 and 
accompanying text; see also supra note 120 and accompanying text (stating that hormones 
“do not exist in nature in the pure form,” are not in “nature’s storehouse,” and had not 
been “previously known” to exist). 
252 See supra note 17 (discussing the USPTO argument that genes are not natural in their 
isolated and purified state and are therefore patentable subject matter); see also supra note 
52 and accompanying text (using the definition of a gene as an open reading frame of a 
sequence of DNA that is the region between the start and stop codons).  When this 
definition is applied, at the most microscopic level, a gene exists in a natural form.  See 
supra Part II.E. 
253 See supra note 53.  It is not the actual gene that is becoming altered, manipulated, and 
changed to the point that it becomes manmade as the USPTO has suggested.  See supra text 
accompanying note 17.  What is actually manipulated and altered are the fragments and 
attachment material, which are not definitional parts of the gene.  See supra Part II.B. 
(describing the particles of a gene).  Therefore, when looking only at the biochemical 
makeup of the gene, the definitional gene occurs in the pure form in nature. This same 
argument could pertain to the steroids in In re Bergstrom.  See 427 F.2d at 1396.  The 
hormones themselves, on the most basic level, remain pure and isolated in the definitional 
sense of the term “hormone.”  See ALBERTS, supra note 46, at G12.  Therefore, the actual 
hormone is not altered, only the material around it is altered, and the hormone remains 
pure in the most microscopic sense of the argument.  Id. at 545. 
254 See In re Bergstrom, 427 F.2d at 1395. 
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inability of courts to withhold patents on naturally occurring substances 
must be addressed to resolve the current problems associated with the 
patentability of genes.255 
C.   Current Problems That Arise From Issuing Patents on Genes 
One of the main reasons for excluding genes from patentable subject 
matter on the basis of their natural occurrence is the public policy 
problems presented by their current incorporation.256  The following Part 
analyzes the different public policy arguments surrounding genes that 
relate to the incentives for invention, economic benefits of investment, 
impairment on scientific research, and a large backlog of the USPTO.257  
Ultimately, the detriments of the patentability of genes outweigh the 
benefits.258 
First, the argument that the ability to issue a patent on human genes 
is necessary to provide an incentive to perform research fails to take into 
account the natural curiosity of mankind and the desire for the United 
States to be the leading nation in science and technology.259  Competition 
is a naturally driven characteristic of mankind that is not necessarily 
sparked by incentive. 260   Furthermore, some of the most important 
inventions have been successfully achieved without the incentive for 
statutory monopolization.261  While incentive for invention may play a 
role in the promotion of certain aspects of science and technology, when 
                                                 
255 See supra Part II.F. 
256 See supra Part II.F. 
257 See infra notes 259–75 and accompanying text. 
258 See infra notes 259–75 and accompanying text. 
259 See supra notes 142–48 and accompanying text; see also CHISUM, supra note 4, at 62 
(discussing that the incentive to invent remains in achieving a patent and a monopoly on 
the patented object); Eisenberg, supra note 149, at 721. 
260 Mankind is naturally drawn to compete both intellectually as well as physically.  
Cynthia Johnson, Children and Competition, 1993 N.C. COOPERATIVE EXTENSION SERV. J. 2, 
available at http://www.ces.ncsu.edu/depts/fcsl/human/pubs/ses404.pdf.  For example, 
children start playing sports at an early age.  Id.  One of the underlying principles in most 
sports is to fulfill the natural desire to compete.  Id.  This desire can also be placed on the 
intellectual level by the desire for America’s youth to be successful in grade school spelling 
bee championships or math competitions.  Id. 
261 The Great Idea Finder, Fascinating Facts About the Invention of the Wheel by 
Mesopotamian’s in c3500 BC, https://www.ideafinder.com/history/inventions/wheel. 
htm (last visited Feb. 22, 2005).  The most classic invention would be the wheel, which was 
evolutionarily invented to make transporting items easier.  Id.  The incentive in this 
invention was to make life essentially easier, not to be granted control over the use and 
future production of the product.  Id.  The suggestion presented here is that 
monopolization is not the only incentive that drives people to develop extremely important 
advances in technology and science.  Id. 
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the product in question is an item as important as the cutting edge of 
biotechnological research, other incentives play a more powerful and 
regulatory role than that achieved by monopolization of the product.262 
The second set of arguments, that a patent is necessary to ensure a 
return on investments and that funding from the private sector will 
disappear because researchers and investors will have an impaired 
ability to earn a return on their investments, does not acknowledge the 
fact that many investments naturally incorporate risks.263  Even as patent 
protection exists today, investing in genetic research is a risky venture 
and it may only remotely be affected by the issuance of patent 
protection.264  Regardless of whether patent protection is offered, the 
effect of scientific research will always be a race to discovery, and 
whoever gets there first will most likely end up with the greatest 
return.265 
The third argument, that failing to allow the issuance of patents on 
genes would impair scientific research, is without merit because the 
issuance of patents is arguably what causes impairment to scientific 
research.266  The concern that a patent is necessary to require a scientist to 
pay expensive royalties to a patent-owning scientist is flawed because 
expensive royalties waste significant financial resources and ultimately 
take part of a valuable commodity away from the field of research.267  
Such money should not be thrown back into an object that has already 
been discovered.268  Scientific research will continually be performed, 
and the money used for royalties should be sent to other areas of 
                                                 
262 For example, when a product is not highly important to civilization and is without 
patent protection, one may not wish to invest the time and effort into the fulfillment of the 
invention; however, when the product is of such great importance to society, such as the 
beneficial medical products of gene research, issuance of a patent may not be the necessary 
incentive for invention.  See Eisenberg, supra note 153, at 1028. 
263 See Looney, supra note 144, at 234 (stating that researchers have provided a significant 
benefit to society and should be rewarded by a large return on their investments of both 
money and time). 
264 See Erramouspe, supra note 152, at 996 (discussing that even with patent protection, an 
underlying sense of competition remains in the field of research to be the first to discover 
because if time and money is invested and someone else discovers first, the time and 
money is lost). 
265 Id.  The opportunity to be the first to discover a workable gene and to put the function 
of that gene into practice could arguably serve as an incentive for investment.  Id.  It is 
likely that investors do not even incorporate the potential grant of a patent on the research 
because being issued a patent is a risk in itself.  Id.  If one does not reach the finish line first, 
he will not be issued a patent and all is lost to the investor.  Id. 
266 See supra notes 149–59 and accompanying text. 
267 See supra note 152 and accompanying text. 
268 See supra note 152 and accompanying text. 
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undeveloped research to increase the speed with which these discoveries 
surface and ultimately benefit society.269  Eliminating patents on genes 
should have the effect of lowering the cost of research by eliminating 
several thousands of dollars in attorney and filing fees, thereby 
significantly lowering the cost involved when a scientist performs 
further research on an already discovered product.270 
The final argument, that genes should be excluded from patentable 
subject matter because the USPTO is backlogged with hundreds of 
thousands of applications at the office, survives scrutiny because the 
beneficial impact of lowering the wait time for an application outweighs 
the suggested impairments created by precluding the patentability of 
genes. 271   Furthermore, if the current backlog of patents remains a 
concern at the USPTO,  the office may eventually need to hire a larger 
staff, which would result in a much higher application fee for all 
inventors wishing to claim a patent.272  High application fees may in turn 
prohibit the applications of other useful inventions as well as raise the 
cost of research on genes to an even higher level in order to cover the 
application cost.273   Such a result would surely hamper, rather than 
promote, the field of discovery because few people would be able to 
afford the very high application cost.274  The first step in preventing these 
policy issues and diminishing the backlog at the USPTO is to remove 
genes from the incorporation of patentable subject matter under the 
Patent Act.275 
Ultimately, the Patent Act needs to be amended to exclude genes 
from patentable subject matter.  For researchers and religious leaders, the 
benefits of removing genes from patentable subject matter far outweigh 
the detriments to investors and biotechnological companies. 276  
Therefore, § 103 of the Patent Act should be amended to ensure that 
                                                 
269 See supra note 153 and accompanying text. 
270 See supra notes 152–53 and accompanying text. 
271 See supra notes 172–76 and accompanying text. 
272 See Rai, supra note 174, at 104 (stating that a possible effect created by the patentability 
of genes is higher application fees due to the need for a larger staff and a longer wait time 
for issuance of patents).  Furthermore, because of the extreme excess of applications 
regarding highly complex gene sequences, higher educated employees with knowledge of 
the subject matter will need to be hired, which can also increase the cost of the patent 
system.  Id. 
273 Id. 
274 Id. 
275 See infra Part IV for a potential solution to the problems created by the patentability of 
genes. 
276 See supra Part II.F. 
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society is not continually harmed by the problems created by the 
patentability of genes.277 
IV. PROPOSED AMENDMENT TO 35 U.S.C. § 103 
As was discussed in Part III, allowing the patentability of genes is 
detrimental to the Patent Act because genes are naturally occurring.278  
Incorporating genes into the Patent Act undermines its goal of 
rewarding invention because the incorporation of genes suggests that 
material obtained without invention is also patentable.279  Furthermore, 
the patentability of genes harms society by impairing scientific research 
and preventing other worthy inventions from obtaining a patent in a 
reasonable amount of time. 280   Consequently, this Note suggests an 
amendment to § 103 of the Patent Act in an attempt to exclude genes 
from patentable subject matter.281 
To accomplish the removal of genes from patentable subject matter, 
§ 103 of the Patent Act should be amended to exclude naturally 
occurring objects and nucleotide sequences, and include a definition for 
the term “composition of matter.”  The amended statute appears as 
follows, with the author’s commentary intertwined: 
Proposed Amendment to 35 U.S.C. § 103282 
(a) A patent may not be obtained though the invention is 
not identically disclosed or described as set forth in 
section 102 of this title, if the differences between the 
subject matter sought to be patented and the prior art 
are such that the subject matter as a whole is naturally 
occurring or would have been obvious at the time the 
invention was made to a person having ordinary skill in 
the art to which said subject matter pertains. 
Patentability shall not be negatived by the manner in 
which the invention was made. 
                                                 
277 See supra Part IV. 
278 See supra Part III.A. 
279 See 35 U.S.C. § 101. 
280 See Rai, supra note 174, at 104. 
281 See infra notes 282–304 and accompanying text. 
282 The proposals are the contributions of the author.  Specifically, proposed additions are 
italicized, and proposed deletions are struck out.  The language in regular font is taken 
from § 103.  See generally 35 U.S.C. § 103. 
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Commentary 
To begin, because the courts have manipulated the term “naturally 
occurring,” the term needs to be directly addressed in the Patent Act.283  
Currently, the term “naturally occurring” is addressed as a condition 
and requirement of the Patent Act and is discussed within previous court 
opinions, where it is often only used as a last resort when an object is not 
otherwise patentable under the novelty and nonobviousness 
standards. 284   The incorporation of the precise term “naturally 
occurring,” as well as a statutory definition, would ensure that the Patent 
Act remains useful for the reasons it was written—to reward invention 
and human ingenuity.285 
Incorporation of the term “naturally occurring” in the 
nonobviousness section of the Patent Act is the most logical place 
because the two exclusions are very similar.286  Furthermore, eliminating 
naturally occurring substances from patentable subject matter in the 
actual text of the Patent Act, as opposed to just mentioning it in the 
interpretive notes, will provide a clear rule for courts to apply.287  If a 
court determines that an object is naturally occurring, it can 
automatically exclude it, rather than use the term “naturally occurring” 
as an excuse  for unpatentability based on some other bar.288   This 
revision will lead to greater uniformity in the application of patent law to 
naturally occurring substances. 
(b)(1) Notwithstanding subsection (a), and upon timely 
election by the applicant for patent to proceed under this 
                                                 
283 See CHISUM, supra note 4, at 62, which states: 
The phrase “product of nature” is on occasion used in a different 
sense—as a shorthand expression of the unpatentability under the 
novelty and nonobviousness standards of (1) an old product derived 
from a new source or process or (2) a new product that differs from old 
ones only in terms of an incremental degree of purity. 
Id. 
284 See 35 U.S.C. § 101; see also supra notes 72–122 (discussing court decisions concerning 
the term); supra note 4 (discussing the requirements for nonobviousness). 
285 See 35 U.S.C. § 101. 
286 See supra text accompanying note 4 (discussing the standard of nonobviousness as the 
inability of one skilled in the art to obtain the invention upon a reasonable attempt).  
Naturally occurring substances could arguably be considered obvious because they already 
exist in nature. 
287 Compare supra Part II.D (discussing the holdings of courts regarding the term 
“naturally occurring”), with supra Part III.B (discussing the possible misapplications of the 
term “naturally occurring” in several different cases). 
288 See CHISUM, supra note 4, at 62. 
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subsection, a biotechnological process using or resulting 
in a composition of matter that is novel under section 
102 and nonobvious under subsection (a) of this section 
shall be considered nonobvious if— 
 (A) claims to the process and the composition of 
matter are contained in either the same application for 
patent or in separate applications having the same 
effective filing date; and 
 (B) the composition of matter, and the process at the 
time it was invented, were owned by the same person or 
subject to an obligation of assignment to the same 
person. 
 (2) A patent issued on a process under paragraph 
(1)— 
 (A) shall also contain the claims to the composition 
of matter used in or made by that process, or 
 (B) shall, if such composition of matter is claimed in 
another patent, be set to expire on the same date as such 
other patent, nothwithstanding section 154 [35 USCS 
§ 154]289 
 (3) For purposes of paragraph (1), the term 
“biotechnological process” means— 
 (A) a process of genetically altering or otherwise 
inducing a single- or multi-celled organism to— 
         (i) express an exogenous nucleotide sequence, 
 (ii) inhibit, eliminate, augment, or alter expression of 
an endogenous nucleotide sequence, or 
 (iii) express a specific physiological characteristic not 
naturally associated with said organism; 
Commentary  
Eliminating the reference to a nucleotide sequence will prevent the 
patenting of genes because genes consist of nucleotides.290  This section 
references paragraph (1), which describes a nucleotide in these 
circumstances as nonobvious.291  However, if the revision made in (a) is 
accomplished, a nucleotide will be considered “naturally occurring” and 
therefore not patentable.292  Maintaining (iii) supports the revision in (a), 
                                                 
289 No changes to section (2) are proposed.  Section (2) above is the original text from the 
statute.  See 35 U.S.C. § 103(b)(2). 
290 See supra Part II.B (discussing several definitions of genes, which include nucleotides). 
291 35 U.S.C. § 101. 
292 See supra Part III.A (discussing genes as natural objects). 
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incorporating the term “naturally occurring” as obvious subject matter, 
because it states that the characteristic must not naturally be associated 
with the organism. 
 (B) cell fusion procedures yielding a cell line that 
expresses a specific protein, such as a monoclonal 
antibody; and 
 (C) a method of using a product produced by a 
process defined by subparagraph (A) or (B), or a 
combination of subparagraphs (A) and (B). 
 (4) For purposes of paragraph (1), the term “composition 
of matter” means— 
the manmade combination or mixing of elements or 
ingredients.  In order for a naturally occurring element to be 
considered a “composition of matter,” it must be combined or 
mixed through manmade manipulation techniques into a new, 
non-naturally occurring form.  Isolated and/or purified 
products do not qualify as “compositions of matter.” 
Commentary 
This revision will also exclude genes from patentable subject 
matter.293  In order for a substance to be patented as a “composition of 
matter,” it will have to result from the incorporation of two or more 
naturally occurring elements into one non-naturally occurring element, 
which would remove genes from this class of patentable subject matter 
because the isolation and purification technique used in gene excision 
does not leave a product that would meet this definition.294  The gene is 
being taken from one piece of matter rather than added to other material.  
The result of removing genes from patentable subject matter, as defined 
by the Patent Act, will prevent many of the concerns regarding public 
policy raised earlier in this Note.295 
Care will be necessary in defining the term “composition of matter” 
to retain many other biotechnological inventions worthy of 
patentability.296  If the definition were to include the suggested elements, 
then the bacteria in Chakrabarty would still qualify as patentable subject 
                                                 
293 See supra note 66 and accompanying text (describing the current incorporation of 
genes into the Patent Act by qualifying them as compositions of matter).  If this suggested 
revision were applicable, genes would no longer fulfill this criteria. 
294 See supra note 108 and accompanying text. 
295 See supra Parts II.F, III.C (discussing the public policy arguments for and against the 
patentability of genes). 
296 See supra Part II.F. 
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matter because two bacteria were combined together to form one 
bacterium that performs in a non-naturally occurring way. 297   The 
biotechnology corporations would be appeased because they could still 
patent any biotechnological alteration involving the addition of 
elements, which would therefore ensure a return on their investments.298 
The main argument against redefining the term “composition of 
matter” would be that not all biochemical inventions taken from one 
piece of matter, rather than added to others, are genes; by eliminating 
genes from patentable subject matter, many other inventions are also 
eliminated.299  For example, the hormones in In re Bergstrom would no 
longer qualify as patentable subject matter. 300   The hormones were 
purified and isolated, thus rendering them patentable.301  However, the 
same arguments regarding the term “naturally occurring” that apply to 
genes can also apply to the hormones presented in In re Bergstrom.302  
Based on the need to disqualify naturally occurring material from 
patentable subject matter because of a lack of inventiveness, it can be 
argued that these materials also should be disqualified.303  This revision 
will help reinforce the ultimate goal of the Patent Act—to reward 
invention by ensuring that only true inventions receive a patent.304 
Ultimately, the proposed amendments to the Patent Act are 
beneficial to society as a whole.  People will only be issued patents on 
material that they have invented, not merely excised from nature.  
Therefore, the underlying premise for the Patent Act, to reward 
invention with a monopoly for several years, will still be applicable.  
Furthermore, biotechnology firms will still have a large array of 
patentable material to work with, which ensures continued returns on 
their research investments.  A final beneficial impact created by the 
proposed amendment is that the public policy concerns dealing with 
                                                 
297 See supra notes 99–100 and accompanying text (discussing the method of forming the 
bacteria for the purpose of achieving the non-natural task of cleaning up oil spills). 
298 See supra Part II.G (discussing the economic incentives argued to be created by the 
patenting of biotechnological processes). 
299 Basically any item obtained from the processes of purification and isolation would be 
excluded.  The same argument regarding “naturally occurring” can be applied to any 
composition that is achieved by this process; however, based on the public policy issues 
regarding the patentability of genes, this Note only addresses this issue. 
300 See In re Bergstrom, 427 F.2d 1394, 1396 (C.C.P.A. 1970) (discussing the isolation and 
purification technique used to purify hormones that were then considered patentable). 
301 See supra notes 114–25 and accompanying text. 
302 See Ong, supra note 1, at 16 (discussing the patentability of several biochemical 
compositions). 
303 Id. 
304 35 U.S.C. § 101. 
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patenting genes will finally be addressed.  Therefore, the proposed 
amendment should survive any threatening arguments. 
V.  CONCLUSION 
The concerns raised by researchers and critics of gene patentability 
addressing the ethical, legal, and moral implications of gene patenting 
are real.  As such, genes need to be removed from the category of 
patentable subject matter.  Genes can and should be removed because 
they are not naturally occurring.  The argument that genes are patentable 
because they are purified and isolated, and thus altered to the point that 
they are manmade, is without merit.  The alteration and purification 
technique does not change the underlying biochemical and functional 
definition of a gene.  Genes are naturally occurring, regardless of 
whether they are in a purified and isolated state, and thus genes should 
not be patented. 
The way to solve this problem is to change the current Patent Act to 
effectuate a greater understanding of the terms “natural” and 
“composition of matter.”  These definitions will ultimately result in more 
uniform applicability of the Patent Act on a national level and will also 
show biotechnology firms and others performing genetic research that 
they need to find other ways to make a return on their investments.  
Overall, the exclusion of genes from patentable subject matter under the 
Patent Act and the establishment of genes as naturally occurring 
manifestations of nature will have a beneficial impact on society and will 
ensure that the Patent Act serves its original purpose—to reward 
invention. 
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